Human EGFR-T790M Stable Cell Line-Ba/F3

Name: Human EGFR-T790M Stable Cell Line-Ba/F3
SKU: CSC-RO0141
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CSC-RO0141

Host Cell : Ba/F3 Size : >1x10⁶ frozen cells/vial

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Cat. No.	CSC-RO0141
Description	Ba/F3-EGFR-T790M cell line is a stably transfected cell line which expresses human epidermal growth factor receptor (EGFR) with T790M mutation.
Target Gene	EGFR
Gene Species	Homo sapiens (Human)
Host Cell	Ba/F3
Host Cell Species	Mus musculus (Mouse)
Applications	Drug screening and biological assays
Biosafety Level	2
Size	>1x10^6 frozen cells/vial, 1 mL
Stability	Stable in culture over a minimum of 10 passages
Quality Control	Negative for bacteria, yeast, fungi and mycoplasma.
Growth Conditions	37 °C, 5% CO₂
Shipping	Dry ice

Thawing & Subculturing Instructions	1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL.
Freeze Medium	Frozen with 70% medium, 20% FBS, 10% DMSO
Growth Properties	Suspension, round
Freezing Instructions	Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage.

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Gene Name	EGFR epidermal growth factor receptor [ Homo sapiens ]
Gene Symbol	EGFR
Synonyms	ERBB; HER1; mENA; ERBB1; PIG61
Gene Description	epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
Gene ID	1956
Uni Prot ID	P00533
m RNA Refseq	NM_005228.3
Protein Refseq	NP_005219.2
Chromosome Location	7p12
Function	ATP binding; MAP kinase kinase kinase activity; actin filament binding; double-stranded DNA binding; enzyme binding; epidermal growth factor-activated receptor activity; epidermal growth factor-activated receptor activity; identical protein binding; contributes_to nitric-oxide synthase regulator activity; protein binding; protein heterodimerization activity; protein phosphatase binding; protein tyrosine kinase activity; protein tyrosine kinase activity; protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; transmembrane signaling receptor activity;
Pathway	Adaptive Immune System, organism-specific biosystem; Adherens junction, organism-specific biosystem; Adherens junction, conserved biosystem; Alpha6-Beta4 Integrin Signaling Pathway, organism-specific biosystem; Androgen Receptor Signaling Pathway, organism-specific biosystem; Arf6 signaling events, organism-specific biosystem; Axon guidance, organism-specific biosystem;
MIM	131550

Quick Inquiry

Background

Case Study

Applications

Q & A

Customer Reviews

The Human EGFR-T790M Stable Cell Line-Ba/F3 is a cell line stably expressing the human epidermal growth factor receptor (EGFR) T790M mutation. Kobayashi et al. originally reported this mutation in 2005. The mutation known as T790M occurs when methionine (M) replaces thymidine (T) at the 790th position of exon 20 of the EGFR gene. This mutation causes changes to the ATP binding site of EGFR, which lowers its affinity for drug binding and causes acquired resistance to tyrosine kinase inhibitors (TKIs).

The main goals of this cell line's research are to clarify the mechanisms of resistance brought about by the T790M mutation and to pinpoint practical methods for getting past it. Numerous investigations have demonstrated how crucial the T790M mutation is to EGFR-TKI resistance. T790M mutations have been found in tumor tissues after EGFR-TKI treatment using a variety of detection techniques, including ARMS, direct sequencing, PCR-RFLP, and qPCR. The detection rates of these mutations range from 44% to 86%, indicating their prevalence as a common mechanism of resistance. Consequently, the Human EGFR-T790M Stable Cell Line-Ba/F3 offers a theoretical foundation for the creation of innovative therapeutic approaches as well as a useful model system for examining the mechanisms underlying TKI resistance.

About 60% of lung cancer patients with sensitizing EGFR mutations and disease progression following first- and second-generation EGFR TKI therapy had the EGFR T790M mutation, which contributes to acquired resistance. To study T790M-positive cell treatment sensitivity, the researchers used patient-derived cell lines such the EGFR-KDDT790M Ba/F3 models. They identified the T790M mutation in a patient whose tumor developed this mutation as a mechanism to resist erlotinib treatment. Their findings suggest that the EGFR C797S mutation may also contribute to resistance against osimertinib, emphasizing the complexity of resistance mechanisms.

Figure 1 describes the characterization of T790M-positive EGFR-KDD Ba/F3 models, highlighting their sensitivity to third-generation EGFR TKIs while demonstrating resistance to first- and second-generation inhibitors. (doi: 10.4143/crt.2021.385) Figure 1. The researchers established various T790M-positive EGFR-KDD Ba/F3 models, including EGFR-KDDD1T, EGFR-KDDD2T, and EGFR-KDDBDT, to characterize the mutation's properties. They conducted cell viability and immunoblot assays, aiming to assess the sensitivity of these cell lines to different EGFR TKIs, revealing significant resistance to first- and second-generation inhibitors. (Lee C, et al., 2021)

The Human EGFR-T790M Stable Cell Line-Ba/F3 from Creative Biogene lets researchers study the mutation's effects in a controlled setting. This cell line is valuable for testing T790M-positive cells' EGFR TKI sensitivity, especially third-generation inhibitors.

1. Research on drug resistance mechanism: Using the human EGFR-T790M stable cell line Ba/F3, we studied the resistance mechanism of EGFR T790M mutation to tyrosine kinase inhibitors (TKIs), revealed its effect on the reduction of drug binding affinity, and provided a theoretical basis and experimental model for overcoming drug resistance.

2. Molecular biology research: In-depth exploration of the changes of EGFR-T790M mutation on the ATP binding site of EGFR protein, analyzed its mechanism of action in the cell signal transduction pathway, and provided a molecular understanding for the formulation of precision treatment strategies.

3. Research on tumor treatment strategies: By studying the growth characteristics and drug sensitivity of EGFR-T790M stable cell lines, we explored new treatment strategies for this mutation and improved the response rate of tumors to targeted therapy.

4. Research on tumor resistance mechanism: By establishing a resistant cell line model, we systematically studied the molecular mechanism and cell biological process of EGFR-T790M mutation in the formation of tumor resistance, and provided new therapeutic targets and strategies for the development of anti-tumor drugs.

5. Clinical translational research: Combined with the test results of clinical samples, verify the clinical manifestations and prognostic value of EGFR-T790M mutation in tumor patients, and promote the clinical application and translation of relevant research results.

Customer Q&As

What is the genetic mutation stability of Human EGFR-T790M Stable Cell Line-Ba/F3? Do mutations drift over long periods of culture?

A: Human EGFR-T790M Stable Cell Line-Ba/F3 has undergone strict gene editing and screening to ensure the high stability of the EGFR-T790M mutation. The cell line is cultured and amplified over multiple generations to ensure mutations do not drift. Experimental data showed that the expression levels and functions of the mutant genes remained consistent during long-term culture (more than 30 generations). This high stability makes it a reliable tool for studying cancer mechanisms and drug screening related to EGFR-T790M mutations.

How does this cell line perform in anti-EGFR inhibitor experiments? Can drug resistance be simulated in the clinic?

A: This cell line specifically mimics the drug resistance caused by the EGFR-T790M mutation, especially showing obvious resistance in experiments against EGFR inhibitors such as erlotinib and gefitinib. This resistance is highly correlated with clinically observed drug resistance in patients, making this cell line an ideal model for studying resistance mechanisms and screening novel drugs against EGFR mutations. The results showed that the cell line showed a consistent drug resistance response when treated with different concentrations of inhibitors.

Are relevant certification and identification reports for cell lines provided?

A: Yes, detailed cell line certification and identification reports are provided. Customers can request STR (short tandem repeat) analysis results, gene mutation detection reports, cell morphology photos and gene expression analysis. These reports are certified by authoritative laboratories to ensure the identity and quality of the cell lines. Customers can use these reports to verify the authenticity and stability of cell lines and ensure the reliability and reproducibility of experimental results.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Customer Reviews

Professional support

I recently used the Human EGFR-T790M Stable Cell Line-Ba/F3 for experiments, and the overall experience was excellent. This cell line stably expresses the T790M mutation of the human epidermal growth factor receptor (EGFR) and provides an important tool for studying EGFR-TKI resistance.

United Kingdom

2020-09-13

Efficient research model

Human EGFR-T790M Stable Cell Line-Ba/F3 is a very efficient research model, especially suitable for studying the mechanism of EGFR-TKI resistance. This cell line stably expresses the T790M mutation of EGFR, simulating a common clinical resistance mechanism. Using this cell line for experiments, I obtained stable and reliable results. The service provided by the merchant was also very timely and professional, and they gave me full support and guidance.

Canada

2022-06-12

Efficient service

The stability and consistency of the cell lines makes my research run more smoothly. The service quality provided by the boss is also very high. They responded quickly and provided professional technical support, which greatly improved my experimental efficiency.

Germany

2022-01-01

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *

Name

Country *

Email *

Related Products

Cat.No.	Product Name	Price
CSC-RO0352	Human MET-Del14-D1228A Stable Cell Line - Ba/F3	Inquiry
CSC-RO0452	Human ERBB2_A775-G776_ins_YVMA Stable Cell Line - MC38	Inquiry
CSC-RO0316	Human EGFR-V769-D770_ins_GE Stable Cell Line - Ba/F3	Inquiry
CSC-RO0348	Human KIT-D816Y Stable Cell Line - Ba/F3	Inquiry
CSC-RO0322	Human EGFR-Y764-V765_ins_HH Stable Cell Line - Ba/F3	Inquiry
CSC-RO0350	Human KIT-Del(V559V560) Stable Cell Line - Ba/F3	Inquiry
CSC-RO0392	Human FLT3-D835F Stable Cell Line - Ba/F3	Inquiry
CSC-RO0431	Human METex14Del Stable Cell Line - Ba/F3	Inquiry
CSC-RO0673	Human MERTK Stable Cell Line - THP-1	Inquiry
CSC-RO0745	Human NRAS-Q61K Stable Cell Line - Ba/F3	Inquiry

Human EGFR-T790M Stable Cell Line-Ba/F3

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Background

Case Study

Applications

Q & A

Customer Reviews

What is the genetic mutation stability of Human EGFR-T790M Stable Cell Line-Ba/F3? Do mutations drift over long periods of culture?

How does this cell line perform in anti-EGFR inhibitor experiments? Can drug resistance be simulated in the clinic?

Are relevant certification and identification reports for cell lines provided?

Professional support

Efficient research model

Efficient service

Related Products

Related Services